
Savient appoints new president and chief executive
pharmafile | July 10, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Ferrari, Savient, cuts
Savient Pharmaceuticals has appointed Louis Ferrari to the role of president and chief executive for the firm.
Ferrari succeeds Savient’s interim chief executive David Norton, who will continue serving as a member of the Savient board of directors.
“Lou has more than 30 years of leadership experience in the pharmaceutical industry and has been an invaluable member of our senior management team,” said Stephen Jaeger, chairman of Savient.
Ferrari (pictured) said: “I am honoured to be given the opportunity to take on the role of president and chief executive of Savient during this critical time in the company’s history. Over the past several months, my colleagues and I have been working closely with the board to develop a plan to better position the company for future growth.”
Savient has also announced reorganisation plans and organisational changes to align its operations and budget which sees the company eliminate approximately 35% of its workforce, effective from September.
In particular, Savient noted that its field force will be restructured to consist of 35 key account managers and three regional business directors. Savient said it does not expect that service levels to patients, doctors or other customers will be impacted by this reduction.
Related Content

Sanofi plans R&D jobs cuts in France
Sanofi chief executive Olivier Brandicourt is reported to be planning hundreds of job cuts across …

Counting the true cost of the Cancer Drugs Fund cuts
Leading figures from the pharma industry and cancer charities reacted with dismay to the recent …

Companies braced for new round of cancer cuts
Several treatments that extend the lives of people with cancer are expected to be removed …






